LXRβ agonist-3 

LXRβ agonist-3 (compound 4-13) is a potent and selective LXRβ (liver X receptor β) agonist, with an EC₅₀ of 0.095 μM. LXRβ agonist-3 efficiently inhibits U87EGFRvIII cell, with an IC₅₀ of 3.75 μM. LXRβ agonist-3 shows antitumor activity, and can inhibit glioblastoma^[1].

EC₅₀: 0.095 ± 0.012 μM (LXRβ) 0.277 ± 0.066 μM (LXRα)^[1]

LXRβ agonist-3 (compound 4-13) (BALB/c mice, 50 mg/kg, IP, daily for 15 days) significantly reduces glioblastoma tumor growth^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

563.66

C₃₀H₃₃N₃O₆S

2413308-63-9

O=C1[C@@]2(C3=CC=CC=C3N1)C(C4=CC(NC5=CC(S(C)(=O)=O)=C(C=C5)CO)=CC=C4)N(CC2)C(OC(C)(C)C)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Chen H, Chen Z, Zhang Z, Li Y, Zhang S, Jiang F, Wei J, Ding P, Zhou H, Gu Q, Xu J. Discovery of new LXRβ agonists as glioblastoma inhibitors. Eur J Med Chem. 2020 May 15;194:112240.  [Content Brief]